Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Status:
Withdrawn
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the
immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver
metastases for patients with microsatellite stable colorectal cancer.